5-Amino-3-<2-aminoaethyl>-indazol | 98953-79-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 5-Amino-3-<2-aminoaethyl>-indazol
• 英文别名: 3-(2-amino-ethyl)-1(2)H-indazol-5-ylamine；3-(2-aminoethyl)-2H-indazol-5-amine
• CAS: 98953-79-8
• 化学式: C₉H₁₂N₄
• 分子量: 176.221
• InChiKey: LCZLUYVSHLDANC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  80.7
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments
  申请人：Esteve Laboratorios Dr. Esteve S.A.

  公开号：EP1676841A1

  公开（公告）日：2006-07-05

  The present invention relates to substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds of general formula I, a process for their preparation, medicaments comprising said substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds as well as the use of said substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT6 receptors.

  本发明涉及通式I的取代吲唑磺胺基和2,3-二氢吲唑磺胺基化合物，其制备方法，包含所述取代吲唑磺胺基和2,3-二氢吲唑磺胺基化合物的药物，以及利用所述取代吲唑磺胺基和2,3-二氢吲唑磺胺基化合物制备药物，该药物特别适用于预防和/或治疗至少部分通过5-HT6受体介导的疾病或疾病。
• Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments
  申请人：Merce Vidal Ramon

  公开号：US20090005417A1

  公开（公告）日：2009-01-01

  The present invention relates to substituted indazolyl sulfonamide and 2,3-dihydroindolyl sulfonamide compounds of general formula I, a process for their preparation, medicaments comprising said substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds as well as the use of said substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT 6 receptors.

  本发明涉及一般式I的取代的吲唑磺酰胺和2,3-二氢吲哚磺酰胺化合物，以及它们的制备方法、包含所述取代的吲唑磺酰胺和2,3-二氢吲哚磺酰胺化合物的药物，以及利用所述取代的吲唑磺酰胺和2,3-二氢吲哚磺酰胺化合物制备药物，特别适用于预防和/或治疗通过5-HT6受体介导的至少部分疾病或疾病的用途。
• Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1902733A1

  公开（公告）日：2008-03-26

  The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least NMDA-receptor ligand, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种由至少一种具有 5-HT6 受体亲和力的化合物和至少一种 NMDA 受体配体组成的活性物质组合、一种包含所述活性物质组合的药物，以及使用所述活性物质组合制造药物。
• SUBSTITUTED INDAZOLYL SULFONAMIDE AND 2,3-DIHYDRO-INDOLYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1869002A1

  公开（公告）日：2007-12-26
• COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY
  申请人：Laboratorios Del. Dr. Esteve, S.A.

  公开号：EP2040755A1

  公开（公告）日：2009-04-01